Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn's disease

• Published in: PloS one Vol. 16; no. 11; p. e0260034
• Main Authors: Irak, Kader, Bayram, Mehmet, Cifci, Sami, Sener, Gulsen
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 17-11-2021; Public Library of Science (PLoS)
• Subjects: Adult; Biology and Life Sciences; Biomarkers - blood; Blood platelets; Blood tests; Calcium-Binding Proteins - blood; CARD Signaling Adaptor Proteins - blood; Case-Control Studies; Cell activation; Chemokine CCL8 - blood; Chemokines; Crohn Disease - blood; Crohn's disease; Development and progression; Diagnosis; Disease; Enzyme-linked immunosorbent assay; Enzymes; Epidemiology; Epithelial cells; Epithelium; Female; Gastroenterology; Health aspects; Homeostasis; Hospitals; Humans; Immune system; Inflammation; Inflammatory bowel diseases; Intestine; Investigations; Lymphocytes; Macrophages; Male; Measurement; Medicine and Health Sciences; Middle Aged; Mucosal immunity; Neutrophils; NOD-like receptors; Pathogenesis; Pathogens; Phagocytes; Regulatory mechanisms (biology); Serum levels; Software; Therapeutic targets; Young Adult; Turkey; Istanbul Turkey; China
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0260034

Crohn's disease (CD) is characterized by malfunction of immune-regulatory mechanisms with disturbed intestinal mucosal homeostasis and increased activation of mucosal immune cells, leading to abnormal secretion of numerous pro- and anti-inflammatory mediators. MCP2/CCL8 is produced by intestinal epithelial cells and macrophages, and is a critical regulator of mucosal inflammation. NLRC4 is expressed in phagocytes and intestinal epithelial cells and is involved in intestinal homeostasis and host defense. However, no study to date has assessed the circulating levels of NLRC4 and MCP2/CCL8 in patients with CD. The study was aimed to investigate the serum levels of MCP2/CCL8 and NLRC4 in patients with active CD. Sixty-nine patients with active CD and 60 healthy participants were included in the study. Serum levels of NLRC4 and MCP2/CCL8 were determined using an enzyme-linked immunosorbent assay. The median serum NLRC4 levels were lower in the patient group than in the controls (71.02 (range, 46.59-85.51) pg/mL vs. 99.43 (range 83.52-137.79) pg/mL) (P < 0.001). The median serum levels of MCP2/CCL8 were decreased in patients with CD (28.68 (range, 20.16-46.0) pg/mL) compared with the controls (59.96 (range, 40.22-105.59) pg/mL) (P < 0.001). Cut-off points of NLRC4 (<81 pg/mL) and MCP2/CCL8 (<40 pg/mL) showed high sensitivity and specificity for identifying active CD. In conclusion, this is the first study to examine circulating levels of MCP2/CCL8 and NLRC4 in patients with active CD. Our results suggest that serum NLRC4 and MCP2/CCL8 levels may be involved in the pathogenesis of CD and may have a protective effect on intestinal homeostasis and inflammation. Serum levels of MCP2/CCL8 and NLRC4 could be used as a diagnostic tool and therapeutic target for CD.